Masimo Corp is a medical technology company. The company oepates in single segment namely Healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. The company sells its products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, and others.
The chart shows the growth of an initial investment of $10,000 in Masimo Corporation, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Masimo Corporation (MASI) has returned 36.76% so far this year and 28.70% over the past 12 months. Looking at the last ten years, MASI has achieved an annualized return of 15.46%, outperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Masimo Corporation (MASI) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 5.16% | 28.50% | 1.51% | 0.40% | ||||||||
| 2025 | 4.12% | 10.02% | -11.85% | -3.19% | -0.64% | 4.34% | -8.48% | -9.17% | 7.70% | -4.49% | 1.66% | -8.56% |
| 2024 | 10.38% | -0.19% | 14.22% | -8.02% | -6.94% | 0.33% | -14.14% | 10.73% | 14.55% | 7.32% | 19.97% | -4.12% |
| 2023 | 13.79% | -2.38% | 2.03% | 2.26% | -14.38% | 1.69% | -25.50% | -5.94% | -24.08% | -7.52% | 15.97% | 24.86% |
| 2022 | -24.45% | -28.84% | -7.30% | -23.65% | 24.78% | -8.21% | 9.64% | 1.90% | -3.57% | -7.17% | 8.92% | 1.20% |
| 2021 | -5.53% | -4.75% | -9.52% | 0.61% | -8.10% | 12.00% | 12.66% | -0.53% | -0.13% | 4.23% | -2.41% | 4.99% |
| 2020 | 7.91% | -5.18% | 6.83% | 22.06% | 13.33% | -4.82% | -3.88% | 0.83% | 5.38% | -5.96% | 12.14% | 4.84% |
| 2019 | 17.85% | 5.56% | 4.46% | -6.34% | -0.09% | 14.18% | 5.23% | -4.22% | -2.36% | -2.07% | 5.88% | 1.76% |
| 2018 | 10.42% | -6.54% | 0.27% | 2.27% | 10.83% | -2.15% | 2.79% | 18.22% | 5.48% | -7.52% | -5.37% | -3.99% |
| 2017 | 7.79% | 22.11% | 2.48% | 10.01% | -15.49% | 4.52% | 3.15% | -11.75% | 2.47% | 0.61% | -0.75% | -4.78% |
| 2016 | 4.08% | 14.53% | 5.75% | 0.40% | 11.44% | 0.24% | -7.03% | 12.49% | 8.81% |
The charts below present risk-adjusted performance metrics for Masimo Corporation (MASI) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of MASI compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Masimo Corporation volatility is 0.38%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 1.70B | 2.63B | 3.04B | 3.21B | 1.71B | 1.40B | 1.15B | 910.24M | 820.53M | 565.01M | 438.66M | 375.95M | 366.10M |
| Equity Attributable To Parent (USD) | 721.20M | 1.05B | 1.36B | 1.34B | 1.41B | 1.17B | 969.07M | 706.91M | 560.24M | 306.00M | 326.47M | 273.08M | 276.83M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | -20.00K | - | - | - | - | 1.74M | -68.00K | 2.59M | 2.84M |
| Equity (USD) | 721.20M | 1.05B | 1.36B | 1.34B | 1.41B | 1.17B | 969.07M | 706.91M | 560.24M | 307.74M | 326.40M | 275.67M | 279.67M |
| Other Non-current Liabilities (USD) | 81.80M | 190.90M | 206.90M | 285.00M | - | - | - | - | - | - | - | - | - |
| Long-term Debt (USD) | 524.30M | 765.20M | 906.00M | 956.70M | - | - | - | - | - | - | - | - | - |
| Noncurrent Liabilities (USD) | 606.10M | 956.10M | 1.11B | 1.24B | 71.08M | 56.04M | 38.15M | 51.76M | 39.92M | 133.37M | 8.47M | 10.74M | 10.49M |
| Other Current Liabilities (USD) | 184.90M | 281.30M | 249.70M | 263.90M | 98.17M | 62.97M | 57.73M | 78.27M | 146.06M | 52.25M | 46.30M | 37.49M | 28.93M |
| Wages (USD) | 83.70M | 83.60M | 62.60M | 89.30M | 71.60M | 54.71M | 49.49M | 39.52M | 43.18M | 33.60M | 29.49M | 25.02M | 19.72M |
| Accounts Payable (USD) | 103.00M | 252.80M | 251.50M | 276.80M | 64.06M | 54.55M | 40.39M | 33.78M | 31.13M | 38.05M | 28.00M | 27.03M | 27.30M |
| Current Liabilities (USD) | 371.60M | 617.70M | 563.80M | 630.00M | 233.84M | 172.22M | 147.61M | 151.57M | 220.37M | 123.89M | 103.79M | 89.54M | 75.95M |
| Liabilities (USD) | 977.70M | 1.57B | 1.68B | 1.87B | 304.91M | 228.25M | 185.75M | 203.32M | 260.29M | 257.27M | 112.26M | 100.28M | 86.44M |
| Other Non-current Assets (USD) | 417.80M | 460.10M | 732.90M | 776.90M | 264.95M | 153.26M | 175.83M | 154.90M | 147.93M | 120.14M | 113.89M | 105.31M | 76.54M |
| Intangible Assets (USD) | - | 558.20M | 652.30M | 722.60M | 73.92M | 27.25M | 27.92M | 27.12M | 29.38M | 27.77M | 28.10M | 27.36M | 11.39M |
| Fixed Assets (USD) | 355.10M | 381.60M | 424.40M | 402.50M | 272.51M | 219.55M | 165.97M | 164.10M | 136.00M | 101.95M | 24.87M | 23.92M | 15.24M |
| Noncurrent Assets (USD) | 772.90M | 1.40B | 1.81B | 1.90B | 611.39M | 400.07M | 369.72M | 346.12M | 313.30M | 249.87M | 166.86M | 156.60M | 103.17M |
| Other Current Assets (USD) | 521.60M | 730.00M | 628.60M | 730.10M | 854.98M | 868.45M | 680.76M | 451.10M | 421.63M | 164.59M | 121.68M | 90.44M | 210.57M |
| Prepaid Expenses (USD) | 24.10M | 36.60M | 58.30M | 77.50M | 30.24M | 11.75M | 10.58M | 17.07M | 13.05M | 9.82M | 9.24M | 6.51M | 6.42M |
| Inventory (USD) | 380.30M | 459.20M | 545.00M | 501.00M | 215.95M | 115.87M | 93.75M | 95.94M | 72.54M | 69.72M | 56.81M | 47.36M | 45.94M |
| Accounts Receivable (USD) | - | - | - | - | - | - | - | - | - | 71.02M | 84.06M | 75.04M | - |
| Current Assets (USD) | 926.00M | 1.23B | 1.23B | 1.31B | 1.10B | 996.06M | 785.10M | 564.12M | 507.23M | 315.14M | 271.80M | 219.35M | 262.94M |
| Assets (USD) | 1.70B | 2.63B | 3.04B | 3.21B | 1.71B | 1.40B | 1.15B | 910.24M | 820.53M | 565.01M | 438.66M | 375.95M | 366.10M |
Monteverde & Associates PC, a class action securities firm, is investigating four merger and acquisition transactions: VYNE Therapeutics' merger with Yarrow Bioscience (VYNE shareholders to own 3% of combined company), Masimo Corporation's sale to Danaher ($180 per share), Independent Bank Corporation's sale to HCB Financial Corp, and HCB Financial Corp's merger with Independent Bank Corporation. The shareholder vote is scheduled for May 1, 2026.
Bridger Management sold its entire $7 million stake in Masimo in Q4 2025, liquidating 47,841 shares after a 12% stock decline. Weeks later, Masimo announced a $9.9 billion acquisition deal at $180 per share, triggering a 34% stock surge. The article highlights the importance of timing in stock market investing and the risks of selling quality companies during temporary weakness.
Monteverde & Associates PC, a class action law firm, is investigating four merger and acquisition transactions: Kennedy-Wilson Holdings' sale to a consortium for $10.90/share, Masimo Corporation's acquisition by Danaher for $180.00/share, Mister Car Wash's sale to MCW Parent LP for $7.00/share, and JFB Construction's merger with Xtend AI Robotics where JFB shareholders will own approximately 19.9% of the combined entity.
Halper Sadeh LLC, an investor rights law firm, is investigating three companies for potential securities law violations and breaches of fiduciary duties. VerifyMe Inc. is under scrutiny for its merger with Open World Ltd, Masimo Corporation for its $180 per share sale to Danaher Corporation, and Valaris Limited for its stock-for-stock transaction with Transocean Ltd. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.
Danaher agreed to acquire Masimo Corporation for $180 per share in an all-cash deal valued at $9.9 billion. The acquisition is expected to be accretive to earnings by $0.15-$0.20 in the first full year and approximately $0.70 by the fifth year, with projected annual synergies exceeding $175 million. Analysts view the deal as having sound financial rationale with strong recurring revenue and margin improvement potential.
Danaher Corp. is reportedly nearing a $9.9 billion acquisition of Masimo Corp., with an announcement potentially coming as early as Tuesday. The deal represents a significant premium to Masimo's $7 billion market cap and follows governance changes driven by activist investors. Masimo shares surged 34.51% on the news, while Danaher shares fell 5.22% in premarket trading.
The global Medical Device Connectivity Market is projected to grow at a CAGR of 23.40% from 2026 to 2032, expanding from USD 2.49 Billion in 2024 to USD 13.4 Billion by 2032. Growth is driven by increasing demand for IoT-enabled healthcare systems, remote patient monitoring, and favorable regulatory frameworks, though high implementation costs and cybersecurity concerns present challenges.
The global pulse oximeter market is valued at USD 3.8 billion in 2025 and is expected to grow to USD 6.76 billion by 2034 at a 6.64% CAGR. North America currently dominates the market, while Asia-Pacific is experiencing rapid growth. Key drivers include rising chronic respiratory diseases, remote patient monitoring advancements, and wearable technology innovations. However, the market faces challenges from accuracy issues with darker skin tones and competition from smartwatches.
Masimo outlined its long-term strategy at the 2025 Investor Day, projecting 7-10% revenue growth and 30% operating margins by 2028. The company aims for $8.00 adjusted EPS and expects to generate $1 billion in operating cash flow from 2026-2028.
Apple experienced significant developments including a record-breaking streaming drama, launching an iPhone Pocket accessory, strengthening sales in China, and being ordered to pay $634 million in a patent infringement case.
